Stock listing
1S1 Stock Price, News, Filings & Events — Viridian Therapeutics, Inc.
Selected listing: 1S1 · GETTEX · EUR · DE
This page tracks Viridian Therapeutics, Inc.'s 1S1:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1S1:GETTEX. 1S1:GETTEX is the stock-level entry point for investors researching Viridian Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Viridian Therapeutics, Inc. (VRDN) is a publicly traded company based in the United States, specializing in innovative therapies. With a market capitalization of approximately $2.13 billion, Viridian focuses on developing treatments for serious diseases. The company is committed to advancing its research and development efforts to improve patient outcomes.
- Ticker
- 1S1:GETTEX
- Asset type
- Stock
- Market cap
- $2.41B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- GETTEX
- Currency
- EUR
Viridian Therapeutics, Inc. 1S1:GETTEX stock context
This page tracks Viridian Therapeutics, Inc.'s 1S1:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1S1:GETTEX. 1S1:GETTEX is the stock-level entry point for investors researching Viridian Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Viridian Therapeutics, Inc. (VRDN) is a publicly traded company based in the United States, specializing in innovative therapies. With a market capitalization of approximately $2.13 billion, Viridian focuses on developing treatments for serious diseases. The company is committed to advancing its research and development efforts to improve patient outcomes.
Latest news from Viridian Therapeutics, Inc.
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
August 6, 2026
Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
July 16, 2026
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stoc...
May 6, 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 5, 2026
Viridian Therapeutics, Inc. earnings calls
Viridian Therapeutics, Inc. (VRDN) Q4 2024 Earnings Call
March 12, 2025 · Replay with transcript and chapters
Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call
May 8, 2024 · Replay with transcript and chapters
Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call
May 9, 2023 · Replay with transcript and chapters
Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Call
March 8, 2023 · Replay with transcript and chapters
Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call
November 14, 2022 · Replay with transcript and chapters
Viridian Therapeutics, Inc. (VRDN) Q2 2022 Earnings Call
August 15, 2022 · Replay with transcript and chapters
Research Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for 1S1:GETTEX.
Viridian Therapeutics, Inc. company profile
View the public company page for Viridian Therapeutics, Inc. on 6ix.
Viridian Therapeutics, Inc. news
Read company news and market updates connected to Viridian Therapeutics, Inc..
Viridian Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Viridian Therapeutics, Inc..
Alternate listings
VRDN:NASDAQ
US · USD
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
A2QMUH:LSX
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
A2QMUH:LS
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
0K1R:LSE
GB · USD
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
1S1:TRADEGATE
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
VRDN:BOATS
US · USD
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
1S1:FWB
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
1S1:DUS
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.
1S1:SWB
DE · EUR
Alternate listing for Viridian Therapeutics, Inc.; the primary context on this page is 1S1:GETTEX.